OMDA vs OPRX

For growth investors, Omada Health (OMDA) is the stronger pick with 53.

2% revenue growth year-over-year, versus 18. 8% for OptimizeRx Corporation (OPRX). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate Omada Health (OMDA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Omada Health (OMDA) delivered a total return of -28.

7%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus OMDA's -28. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Omada Health (OMDA) is the lower-risk stock at 1.

31β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 74% more volatile than OMDA relative to the S&P 500.

By revenue growth (latest reported year), Omada Health (OMDA) is pulling ahead at 53.

2% versus 18. 8% for OptimizeRx Corporation (OPRX). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 74. 1% for Omada Health. Over a 3-year CAGR, OMDA leads at 42. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -4. 9% for Omada Health — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -4. 6% for OMDA. At the gross margin level — before operating expenses — OPRX leads at 67. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OPRX: 156.

4% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Omada Health (OMDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OMDA: -28. 7%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.